Evidence map›Paper›PMID 38577791›Full record

ArticleClinical chemistry and laboratory medicine2024

Exploring evolutionary trajectories in ovarian cancer patients by longitudinal analysis of ctDNA.

Oliver Kutz, Stephan Drukewitz, Alexander Krüger, Daniela Aust, Doreen William, Sandra Oster, Evelin Schröck, Gustavo Baretton, Theresa Link, Pauline Wimberger and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical chemistry and laboratory medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Oliver KutzDepartment of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, 9169 Technische Universität Dresden , Dresden, Germany.
Stephan Drukewitz9169 National Center for Tumour Diseases (NCT) , Dresden, Germany.
Alexander Krüger9169 National Center for Tumour Diseases (NCT) , Dresden, Germany.
Daniela Aust9169 National Center for Tumour Diseases (NCT) , Dresden, Germany.
Doreen William9169 National Center for Tumour Diseases (NCT) , Dresden, Germany.
Sandra Oster9169 National Center for Tumour Diseases (NCT) , Dresden, Germany.
Evelin Schröck9169 National Center for Tumour Diseases (NCT) , Dresden, Germany.
Gustavo Baretton9169 National Center for Tumour Diseases (NCT) , Dresden, Germany.
Theresa LinkDepartment of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, 9169 Technische Universität Dresden , Dresden, Germany.
Pauline WimbergerDepartment of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, 9169 Technische Universität Dresden , Dresden, Germany.
Jan Dominik KuhlmannDepartment of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, 9169 Technische Universität Dresden , Dresden, Germany.
Deutschen Konsortium für Translationale Krebsforschung · DEGerman Cancer Research Center · DEGerman Cancer Society · DEHeidelberg University · DEHelmholtz-Zentrum Dresden-Rossendorf · DETechnische Universität Dresden · DEUniversity Hospital Carl Gustav Carus · DE

Funding

Deutsche Krebshilfe 70113616Deutsche Krebshilfe 70113636
6 · The paper itself

Abstract

objectivesWe analysed whether temporal heterogeneity of ctDNA encodes evolutionary patterns in ovarian cancer.

methodsTargeted sequencing of 275 cancer-associated genes was performed in a primary tumor biopsy and in ctDNA of six longitudinal plasma samples from 15 patients, using the Illumina platform.

resultsWhile there was low overall concordance between the mutational spectrum of the primary tumor biopsies vs. ctDNA, TP53 variants were the most commonly shared somatic alterations. Up to three variant clusters were detected in each tumor biopsy, likely representing predominant clones of the primary tumor, most of them harbouring a TP53 variant. By tracing these clusters in ctDNA, we propose that liquid biopsy may allow to assess the contribution of ancestral clones of the tumor to relapsed abdominal masses, revealing two evolutionary patterns. In pattern#1, clusters detected in the primary tumor biopsy were likely relapse seeding clones, as they contributed a major share to ctDNA at relapse. In pattern#2, similar clusters were present in tumors and ctDNA; however, they were entirely cleared from liquid biopsy after chemotherapy and were undetectable at relapse. ctDNA private variants were present among both patterns, with some of them mirroring subclonal expansions after chemotherapy.

conclusionsWe demonstrate that tracing the temporal heterogeneity of ctDNA, even below exome scale resolution, deciphers evolutionary trajectories in ovarian cancer. Furthermore, we describe two evolutionary patterns that may help to identify relapse seeding clones for targeted therapy.

Indexed as

Circulating Tumor DNAOvarian NeoplasmsAgedFemaleHumansLongitudinal StudiesMiddle AgedMutationTumor Suppressor Protein p53Circulating Tumor DNATumor Suppressor Protein p53ctDNAliquid biopsyovarian cancertumor evolution

Identifiers

PMID38577791
OpenAlexW4393934055

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.